SK148298A3 - Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) - Google Patents

Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) Download PDF

Info

Publication number
SK148298A3
SK148298A3 SK1482-98A SK148298A SK148298A3 SK 148298 A3 SK148298 A3 SK 148298A3 SK 148298 A SK148298 A SK 148298A SK 148298 A3 SK148298 A3 SK 148298A3
Authority
SK
Slovakia
Prior art keywords
alkyl
formula
carbon atoms
ethyl
alkenyl
Prior art date
Application number
SK1482-98A
Other languages
English (en)
Slovak (sk)
Inventor
Anthony Marfat
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK148298A3 publication Critical patent/SK148298A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SK1482-98A 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) SK148298A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1686196P 1996-05-03 1996-05-03
PCT/IB1997/000323 WO1997042174A1 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Publications (1)

Publication Number Publication Date
SK148298A3 true SK148298A3 (en) 2000-02-14

Family

ID=21779401

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1482-98A SK148298A3 (en) 1996-05-03 1997-04-01 Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)

Country Status (42)

Country Link
US (2) US6211222B1 (es)
EP (1) EP0912521B1 (es)
JP (1) JP3148254B2 (es)
KR (1) KR100339935B1 (es)
CN (2) CN1112359C (es)
AP (4) AP2001002304A0 (es)
AR (1) AR006906A1 (es)
AT (1) ATE292626T1 (es)
AU (1) AU725576B2 (es)
BG (1) BG64211B1 (es)
BR (1) BR9709051A (es)
CA (2) CA2252982C (es)
CO (1) CO4650038A1 (es)
CZ (1) CZ292825B6 (es)
DE (1) DE69732966T2 (es)
DZ (1) DZ2217A1 (es)
EA (1) EA002272B1 (es)
ES (1) ES2238079T3 (es)
GT (1) GT199700043A (es)
HK (1) HK1019443A1 (es)
HN (1) HN1997000046A (es)
HR (1) HRP970227B1 (es)
HU (1) HUP9902459A3 (es)
ID (1) ID16856A (es)
IL (2) IL152083A0 (es)
IS (1) IS4871A (es)
MA (1) MA24158A1 (es)
MY (1) MY132499A (es)
NO (1) NO312959B1 (es)
NZ (1) NZ332240A (es)
OA (1) OA10904A (es)
PE (1) PE64598A1 (es)
PL (1) PL329836A1 (es)
SK (1) SK148298A3 (es)
TN (1) TNSN97070A1 (es)
TR (1) TR199802202T2 (es)
TW (1) TW449585B (es)
UA (1) UA65536C2 (es)
UY (1) UY24532A1 (es)
WO (1) WO1997042174A1 (es)
YU (1) YU16397A (es)
ZA (1) ZA973804B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
US6005118A (en) * 1996-05-03 1999-12-21 Caron; Stephane Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
EP0983249B1 (en) * 1997-05-08 2002-03-13 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives
IL126745A (en) * 1997-11-04 2003-09-17 Pfizer Prod Inc Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors
CA2309150A1 (en) * 1997-11-04 1999-05-14 Pfizer Products Inc. Indazole bioisostere replacement of catechol in therapeutically active compounds
BR9813938A (pt) * 1997-11-04 2000-09-26 Pfizer Prod Inc Compostos terapeuticamente ativos baseados na substituição bioisóstera de indazol por catecol em inibidores de pde4
IL132407A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Method for treating congestive heart failure
JP2000198734A (ja) * 1998-12-30 2000-07-18 Pfizer Inc 胃運動性減弱および関連疾患の治療のための運動性増強薬
ATE290002T1 (de) * 1999-12-23 2005-03-15 Icos Corp Cyclische amp spezifische phosphodiesterase inhibitoren
US6362213B1 (en) 1999-12-23 2002-03-26 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
EP1908463B1 (en) 2001-12-14 2011-09-28 Merck Serono SA Methods of inducing ovulation using a non-polypeptide camp level modulator
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
US7196082B2 (en) * 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US20050019366A1 (en) * 2002-12-31 2005-01-27 Zeldis Jerome B. Drug-coated stents and methods of use therefor
DE10318610A1 (de) 2003-04-24 2004-11-11 Elbion Ag 7-Azaindole und deren Verwendung als Therapeutika
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
US20070004777A1 (en) * 2005-03-23 2007-01-04 Bhagwat Shripad S Methods for treating or preventing acute myelogenous leukemia
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
KR101484025B1 (ko) * 2006-04-21 2015-01-19 얀센 바이오테크 인코포레이티드 염증성 질환의 치료를 위한 ｃｘｃｌ１３ 길항제 및 이의 용도
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
MX2020004836A (es) 2017-11-06 2020-10-16 Rapt Therapeutics Inc Agentes anticancerígenos.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994890A (en) * 1974-01-31 1976-11-30 Chugai Seiyaku Kabushiki Kaisha 1-Aminoalkyl, 3-phenyl indazoles
JPS5654437A (en) * 1979-10-09 1981-05-14 Konishiroku Photo Ind Co Ltd Direct positive image forming method
GB8707051D0 (en) * 1986-04-15 1987-04-29 Ici America Inc Heterocyclic carboxamides
JP2525286B2 (ja) * 1990-11-26 1996-08-14 日本原子力研究所 超耐熱性炭化ケイ素繊維の製造方法
TW223004B (es) * 1991-11-25 1994-05-01 Sumitomo Chemical Co
DK0630367T3 (da) * 1992-03-09 2000-09-18 Zeneca Ltd Hidtil ukendte arylindazoler og deres anvendelse som herbicider
US5444038A (en) * 1992-03-09 1995-08-22 Zeneca Limited Arylindazoles and their use as herbicides
EP0633776B1 (en) * 1992-04-02 2001-05-09 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases
US5554620A (en) * 1993-09-14 1996-09-10 Sterling Winthrop Inc. Substituted 6,11-ethano-6,11-dihydrobenzo[b] quinolizinium salts and compositions and methods of use thereof
US5440038A (en) * 1993-12-07 1995-08-08 Miles Inc. Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones
HUT77517A (hu) * 1994-10-20 1998-05-28 Pfizer Inc. Biciklusos tetrahidro-pirazolo-piridin-származékok, alkalmazásuk és ilyen vegyületeket tartalmazó gyógyászati készítmények
AU709965B2 (en) * 1994-10-21 1999-09-09 Elisha Holding Llc Corrosion preventing buffersystem for metal products
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
EP0983249B1 (en) * 1997-05-08 2002-03-13 Pfizer Products Inc. Processes and intermediates for preparing substituted indazole derivatives

Also Published As

Publication number Publication date
AP0102304A0 (en) 1997-11-03
NZ332240A (en) 2000-07-28
EA199800882A1 (ru) 1999-06-24
TR199802202T2 (xx) 1999-02-22
OA10904A (en) 2001-10-11
IL126547A (en) 2003-03-12
AP1147A (en) 2003-02-25
AP2001002294A0 (en) 2001-12-31
DE69732966D1 (de) 2005-05-12
CZ292825B6 (cs) 2003-12-17
CN1217714A (zh) 1999-05-26
CA2252982A1 (en) 1997-11-13
JP3148254B2 (ja) 2001-03-19
EP0912521B1 (en) 2005-04-06
BG64211B1 (bg) 2004-05-31
PE64598A1 (es) 1998-10-26
DE69732966T2 (de) 2005-09-08
HRP970227B1 (en) 2002-06-30
DZ2217A1 (fr) 2002-12-03
AU725576B2 (en) 2000-10-12
HN1997000046A (es) 1997-06-26
CA2252982C (en) 2002-10-08
MA24158A1 (fr) 1997-12-31
ID16856A (id) 1997-11-13
KR100339935B1 (ko) 2002-07-18
BG102946A (en) 1999-11-30
CO4650038A1 (es) 1998-09-03
BR9709051A (pt) 1999-08-03
CA2389918A1 (en) 1997-11-13
HUP9902459A2 (hu) 1999-11-29
ES2238079T3 (es) 2005-08-16
HRP970227A2 (en) 2000-12-31
AP9700975A0 (en) 1997-07-31
UY24532A1 (es) 2000-09-29
US6127398A (en) 2000-10-03
ATE292626T1 (de) 2005-04-15
PL329836A1 (en) 1999-04-12
GT199700043A (es) 1998-10-02
AU1937397A (en) 1997-11-26
AP2001002304A0 (en) 2001-12-31
NO985095L (no) 1998-12-29
HUP9902459A3 (en) 2001-10-29
EA002272B1 (ru) 2002-02-28
CN1422849A (zh) 2003-06-11
HK1019443A1 (en) 2000-02-11
AP1146A (en) 2003-02-25
WO1997042174A1 (en) 1997-11-13
EP0912521A1 (en) 1999-05-06
AR006906A1 (es) 1999-09-29
NO312959B1 (no) 2002-07-22
TW449585B (en) 2001-08-11
CN1112359C (zh) 2003-06-25
MY132499A (en) 2007-10-31
US6211222B1 (en) 2001-04-03
IL152083A0 (en) 2003-05-29
CZ349298A3 (cs) 1999-09-15
TNSN97070A1 (fr) 2005-03-15
KR20000010751A (ko) 2000-02-25
NO985095D0 (no) 1998-11-02
UA65536C2 (en) 2004-04-15
ZA973804B (en) 1998-11-02
YU16397A (sh) 1999-12-27
IS4871A (is) 1998-10-16
JPH11508284A (ja) 1999-07-21
IL126547A0 (en) 1999-08-17

Similar Documents

Publication Publication Date Title
SK148298A3 (en) Substituted indazole derivatives and their use as inhibitors phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
AP1025A (en) The invention relates to compounds of the formula
EP0672031B1 (en) Catechol diethers as selective pde iv inhibitors
JP3032840B2 (ja) 置換インダゾール誘導体
SK27299A3 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
JPH08504435A (ja) タキキニン受容体拮抗剤としての４−アミノメチル／チオメチル／スルホニルメチル−４−フェニルピペリジン
CZ20001623A3 (cs) Terapeuticky účinné látky na bázi nahrazení katecholu indazolovým bioisosterem v inhibitorech PDE4
WO2003076408A2 (en) Indazole derivatives that are activators of soluble guanylate cyclase
US20040048866A1 (en) Indazole derivatives that are activators of soluble guanylate cyclase
CZ71099A3 (cs) Deriváty indazolu, farmaceutické kompozice na jejich bázi, meziprodukty a způsob léčení chorob